Aquestive Therapeutics Inc. (AQST)
NASDAQ (NMS) NASDAQ (NMS) Primary 
Is Aquestive Therapeutics (AQST) Stock Outpacing Its Medical Peers This Year?
Here is how Aquestive Therapeutics (AQST) and Arbutus Biopharma (ABUS) have performed compared to their sector so far this year.
Aquestive Therapeutics, Inc. (AQST) Q2 2025 Earnings Call Transcript
Aquestive Therapeutics, Inc. (NASDAQ:AQST ) Q2 2025 Earnings Conference Call August 12, 2025 8:00 AM ET Company Participants A. Ernest Toth - Chief Financial Officer Carl N.
Compared to Estimates, Aquestive Therapeutics (AQST) Q2 Earnings: A Look at Key Metrics
While the top- and bottom-line numbers for Aquestive Therapeutics (AQST) give a sense of how the business performed in the quarter ended June 2025, it could be worth looking at how some of its key metrics compare to Wall Street estimates and year-ago values.
Aquestive Therapeutics (AQST) Reports Q2 Loss, Lags Revenue Estimates
Aquestive Therapeutics (AQST) came out with a quarterly loss of $0.14 per share versus the Zacks Consensus Estimate of a loss of $0.18. This compares to a loss of $0.03 per share a year ago.
Aquestive Therapeutics: Updating The Anaphylm Timeline To Approval
Anaphylm's FDA approval process is a major catalyst, with a PDUFA date set for January 31, 2026, and potential AdCom or partnership news ahead. Anaphylm offers a needle-free, orally delivered epinephrine alternative, boasting rapid absorption and strong clinical data, supporting high approval confidence. If approved, Anaphylm could drive significant revenue growth and a potential company rerating, with peak sales estimates up to $1B and substantial upside from current levels.
These 2 Medical Stocks Could Beat Earnings: Why They Should Be on Your Radar
The Zacks Earnings ESP is a great way to find potential earnings surprises. Why investors should take advantage now.
Aquestive Therapeutics: Anaphylm Could Gain Significant Market Share
Aquestive Therapeutics' Anaphylm offers a unique, non-injectable epinephrine solution for anaphylaxis, with NDA decision expected imminently. Anaphylm's advantages—wallet portability, rapid onset, and high patient/provider preference—position it to capture significant share of a $2B U.S. market. My risk-adjusted DCF analysis values AQST at $5/share ( at just 10% market share), indicating the stock is undervalued at current levels.
Aquestive Therapeutics (AQST) Reports Q1 Earnings: What Key Metrics Have to Say
While the top- and bottom-line numbers for Aquestive Therapeutics (AQST) give a sense of how the business performed in the quarter ended March 2025, it could be worth looking at how some of its key metrics compare to Wall Street estimates and year-ago values.
Aquestive Therapeutics (AQST) Reports Q1 Loss, Lags Revenue Estimates
Aquestive Therapeutics (AQST) came out with a quarterly loss of $0.24 per share versus the Zacks Consensus Estimate of a loss of $0.17. This compares to loss of $0.17 per share a year ago.
Aquestive Therapeutics: Unprofitable For A Few More Years, But Significant Upside Potential
AQST's Anaphylm, a sublingual epinephrine film, shows strong potential with FDA approval expected in Q2'25 and a $1B annual revenue target. AQST's financial health is weaker compared to competitors, with a probable need to raise $100M-$150M in the next 2-3 years. My base-case DCF model estimates a fair value of $8.11, offering a 179% upside, with an optimistic scenario reaching $15.38.
Aquestive Therapeutics: Oral Anaphylaxis NDA Opportunity Spells Buy
Aquestive currently plays small ball with a handful of approved products that offer no adequate financial potential. Its recently approved Libervant, which offered greater revenue opportunity, is mired in litigation. Aquestive's Anaphylm, which is set for an imminent FDA filing, has blockbuster potential.
Aquestive Therapeutics, Inc. (AQST) Q4 2024 Earnings Call Transcript
Aquestive Therapeutics, Inc. (NASDAQ:AQST ) Q4 2024 Results Conference Call March 6, 2025 8:00 AM ET Company Participants Brian Korb - IR Dan Barber - CEO Ernie Toth - CFO Sherry Korczynski - SVP of Sales and Marketing Carl Kraus - CMO Conference Call Participants David Amsellem - Piper Sandler Francois Brisebois - Oppenheimer Kristen Kluska - Cantor Fitzgerald Jason Butler - JMP Securities Raghuram Selvaraju - HC Wainwright & Co. Gary Nachman - Raymond James Thomas Flaten - Lake Street Capital Markets James Molloy - Alliance Global Partners Operator Good day, and thank you for standing by. Welcome to the Fourth Quarter 2024 Aquestive Therapeutics Earnings Conference Call.
